medigraphic.com
Centro Universitario de Ciencias de la Salud de la Universidad de Guadalajara y del OPD Hospitales Civiles de Guadalajara

2007, Number 1

<< Back Next >>

Inv Salud 2007; 9 (1)

Use of midazolam in the pediatrical units of intensive therapy

Delgado OMA

Language: Spanish
References: 7
Page: 8-9
PDF size: 476.40 Kb.


ABSTRACT

There are numerous factors that contribute to the anxiety and stress in the intensive pediatric care units. Midazolam is an imidazolbenzodiacepine that affects by depressing the central nervous system including the limbic system and the reticular formation. It produces a reversible increasing action of the γ-aminobutirico acid (GABA), having such uses as a sedative, ansiolytic, anticonvulsant and muscle relaxant. It is usually administered in a continuous infusion, 100-400 µg/kg/h, and becomes active within 2-3 min after administration with an estimated duration of 30 min.It has an extensive hepatic metabolism because of it is cytochrome P450 isoforms. The main side effects of midazolam is respiratory distress, paradox agitation, and occasionally hypotension, among others. Basically it is a benzodiazepine with a safe short life, effective for sedation in pediatric intensive care patients with significant benefits for them.


REFERENCES

  1. Chamorro J-C. Analgesia, sedación y bloqueo neuromuscular en la sepsis. Rev Eelect Med Intens 2005; C25, N.1

  2. Sharon E. Mace, et al. Clinical policy: Evidence-based approach to pharmacologic agents used in pediatric sedation and analgesia in the emergency department. Ann Emerg. Med 2004; 44: 342-377

  3. Twite M. D., MA BChir, Rashid A., Zuk J., Friesen R. H. Sedation, analgesia, and neuromuscular blockade in the pediatric intensive care unit: Survey of fellowship training programs. Ped crit care med 2004; 5, Num 6.

  4. Wildt S. N., Hoog M., Vinks A., PharmD, Giesen E. van der, MSc; Van Den Anker J. N. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med; 2003; 31, Num 7

  5. Vender J., Szokol J., Murphy G., Nitsun M. Sedation, analgesia and neuromuscular blockade in sepsis: An evidence-based review. Crit Care Med 2004; 32 Num 11.

  6. Cuthriell A. M, Pediatric Pharmacotherapy. Midazolam: Use in the Pediatric Intensive Care Population. Children’s Med Center Univ Virg 2000;6, Num 1

  7. Taketomo C. K., Hodding J., Kraus D. “Midazolam”. Manual de prescripcion pediatrica. 11° ed. Mexico. Editorial Intersistemas. 2005. Pag. 769-772




2020     |     www.medigraphic.com